AtheroGenics files for Chapter 11
This article was originally published in Scrip
Executive Summary
AtheroGenics has filed for Chapter 11 bankruptcy, saying that its "substantial debt burden" has impeded its ability to develop its lead product AGI-1067, a novel anti-inflammatory. The US company has agreed to the Involuntary Chapter 7 Petition filed by its creditors on September 15th.